Quoin Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Quoin Pharmaceuticals's earnings have been declining at an average annual rate of -16.6%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-16.6%
Earnings growth rate
24.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -153.4% |
| Net Margin | n/a |
| Next Earnings Update | 09 May 2024 |
Revenue & Expenses BreakdownBeta
How Quoin Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -9 | 6 | 3 |
| 30 Sep 23 | 0 | -9 | 6 | 3 |
| 30 Jun 23 | 0 | -10 | 6 | 3 |
| 31 Mar 23 | 0 | -10 | 7 | 3 |
| 31 Dec 22 | 0 | -9 | 7 | 3 |
| 30 Sep 22 | 0 | -19 | 7 | 3 |
| 30 Jun 22 | 0 | -18 | 7 | 3 |
| 31 Mar 22 | 0 | -19 | 5 | 2 |
| 31 Dec 21 | 0 | -21 | 4 | 2 |
| 30 Sep 21 | 0 | -11 | 3 | 1 |
| 30 Jun 21 | 0 | -10 | 2 | 0 |
| 31 Mar 21 | 0 | -6 | 2 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
Quality Earnings: QNRX is currently unprofitable.
Growing Profit Margin: QNRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QNRX is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare QNRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QNRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: QNRX has a negative Return on Equity (-153.36%), as it is currently unprofitable.